February 7, 2024

Nationwide Population Study Finds Lisdexamphetamine is Associated with Significantly Lower Risk of Hospitalization and Death Among Persons with Methamphetamine and Amphetamine Use Disorders

Unprescribed amphetamines are the second most commonly used illicit drugs worldwide. Persons with methamphetamine or amphetamine use disorders (MAUD) have elevated rates of mortality, primarily from acute poisoning, but also from suicide, homicide, cardiovascular disease, and injuries. Illicit amphetamine use is also associated with aggressive behavior and criminality.

There are presently no approved pharmacological interventions for treating MAUD. 

A Finnish study team used the Swedish national registers to explore relationships between various drug treatments, including ADHD medications, and hard outcomes – hospitalization and death – among persons with MAUD.

The team looked at all Swedish residents aged 16 to 64 years with a registered first-time treatment contact due to MAUD between July 1, 2006 and December 31, 2018. They matched this cohort with data from the Prescribed Drug Register from July 2005 to December 2018.

They adjusted for the following confounding variables: age, sex, education, granted disability pension, long-term sickness absence during previous year (more than 90 days), and medication-related comorbidities.

The cohort consisted of 13,965 persons diagnosed with MAUD. Of these, 11,492 (about three out of four) were either hospitalized (10,341) or died (1,151) in the follow-up period.

The study looked at a variety of prescription drugs, including six ADHD medications: methylphenidate, atomoxetine, modafinil, amphetamine, dexamphetamine, and lisdexamphetamine. Prescriptions for none of these were significantly associated with higher risk of hospitalization or death from substance used disorder.

On the other hand, persons diagnosed with MAUD but prescribed lisdexamphetamine were in all instances at significantly lower risk. Lisdexamphetamine users were 18% less likely to be hospitalized for substance use disorder in within-individual and 25% less likely to be hospitalized in between-individual analyses. Lisdexamphetamine users also had half the risk of all-cause mortality

The authors concluded, “In this Swedish nationwide cohort study, use of lisdexamphetamine was consistently associated with a reduction in risk of death and hospitalization in persons with amphetamine or methamphetamine. Use of antidepressants were associated with an increase in risk of hospitalization due to SUD and any hospitalization or death. Benzodiazepine use was associated with poor outcomes.”

Milja Heikkinen, Heidi Taipale, Antti Tanskanen, Ellenor Mittendorfer-Rutz, Markku Lähteenvuo, and Jari Tiihonen, “Association of Pharmacological Treatments and Hospitalization

and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients,” JAMA Psychiatry (2022), https://doi.org/10.1001/jamapsychiatry.2022.3788.

Related posts

No items found.

The Role of Serotonin in ADHD and Its Many Comorbidities

Serotonin is a key chemical in the body that helps regulate mood, behavior, and also many physical functions such as sleep and digestion. It has also been linked to how ADHD (attention-deficit/hyperactivity disorder) develops in the brain. This study looks at how serotonin may be involved in both the mental health and physical health conditions that often occur alongside ADHD.

It is well-established that ADHD is more than just trouble focusing or staying still. For many, it brings along a host of other physical and mental health challenges. It is very common for those with ADHD to also have other diagnosed disorders. For example, those with ADHD are often also diagnosed with depression, anxiety, or sleep disorders. When these issues overlap, they are called comorbidities. 

A new comprehensive review, led by Dr. Stephen V. Faraone and colleagues, delves into how serotonin (5-HT), a major brain chemical, may be at the heart of many of these common comorbidities.

Wait! I thought ADHD had to do with Dopamine–Why are we looking at Serotonin?

Serotonin is a neurotransmitter most often linked to mood, but its role in regulating the body has much broader implications. It regulates sleep, digestion, metabolism, hormonal balance, and even immune responses. Although ADHD has long been associated with dopamine and norepinephrine dysregulation, this review suggests that serotonin also plays a central role, especially when it comes to comorbid conditions.

The Study:

  • Objective: To systematically review which conditions commonly co-occur with ADHD and determine whether serotonin dysfunction might be a common thread linking them.

  • Method: The authors combed through existing literature up to March 2024, analyzing evidence for serotonin involvement in each comorbidity associated with ADHD.

  • Scope: 182 psychiatric and somatic conditions were found to frequently occur in people with ADHD.

Key Findings

  • 74% of Comorbidities Linked to Serotonin: Of the 182 comorbidities identified, 135 showed evidence of serotonergic involvement—91 psychiatric and 44 somatic (physical) conditions.

  • Psychiatric Comorbidities: These include anxiety disorders, depression, bipolar disorder, and obsessive-compulsive disorder—all of which have long-standing associations with serotoninergic dysfunction.

  • Somatic Comorbidities: Conditions like irritable bowel syndrome (IBS), migraines, and certain sleep disorders also showed a significant serotonergic link.

This research suggests that serotonin dysregulation could explain the diverse and sometimes puzzling range of symptoms seen in ADHD patients. It supports a more integrative model of ADHD—one that goes beyond the brain’s attention, reward and executive control circuits and considers broader physiological and psychological health.

future research into the role of serotonin could help develop more tailored interventions, especially for patients who don't respond well to stimulant medications. Future studies may focus on serotonin’s role in early ADHD development and how it interacts with environmental and genetic factors.

The Take-Away: 

This study is a strong reminder that ADHD is a complex, multifaceted condition. Differential diagnosis is crucial to properly diagnosing and treating ADHD. Clinicians' understanding of the underlying link between ADHD and its common comorbidities may help future ADHD patients receive the individualized care they need. By shedding light on serotonin’s wide-reaching influence, this study may provide a valuable roadmap for improving how we diagnose and treat those with complex comorbidities in the future. 

July 14, 2025

Undiagnosed ADHD May Be Undermining Diabetes Control in Adults with Type 1 Diabetes

Our recent study, published in the Journal of Clinical Medicine, aims to shed light on an under-recognized challenge faced by many adults with Type 1 diabetes (T1D): attention-deficit/hyperactivity disorder (ADHD) symptoms.

We surveyed over 2,000 adults with T1D using the Adult Self-Report Scale (ASRS) for ADHD and analyzed their medical records. Of those who responded, nearly one-third met the criteria for ADHD symptoms—far higher than the general population average. Notably, only about 15% had a formal diagnosis or were receiving treatment.

The findings are striking: individuals with higher ADHD symptom scores had significantly worse blood sugar control, as indicated by higher HbA1c levels. Those flagged as "ASRS positive" were more than twice as likely to have poor glycemic control (HbA1c ≥ 8.0%). They also reported higher levels of depressive symptoms.

As expected, ADHD symptoms decreased with age but remained more common than in the general public. No strong links were found between ADHD symptoms and other cardiometabolic issues.

This study highlights a previously overlooked yet highly significant factor in diabetes management. ADHD-related difficulties—such as forgetfulness, inattention, or impulsivity—can make managing a complex condition like T1D more difficult. The researchers call for more screening and awareness of ADHD in adults with diabetes, which could lead to better mental health and improved blood sugar outcomes.

Takeaway: If you or a loved one with T1D struggles with focus, organization, or consistent self-care, it may be worth exploring whether ADHD could be part of the picture. Early identification and support are crucial to managing this common comorbidity. 

July 10, 2025

Norwegian Population Study Finds ADHD Associated with Much Higher Odds of Contact with Child Welfare Services

Background:

This nationwide population study by a Norwegian team aimed to evaluate the relationship between ADHD and various types of child welfare services contacts over a long-term period of up to 18 years among children and adolescents aged 5 to 18 years diagnosed with ADHD, in comparison to the general population within the same age group. 

Norway has a single-payer national health insurance system that fully covers virtually the entirety of its population. In combination with a system of national population and health registers, this facilitates nationwide population studies, overcoming the limitations of relying on population sampling. 

Study:

The study population included all 8,051 children and adolescents aged 5 to 18 who were diagnosed with ADHD for the first time in the Norwegian Patient Registry between 2009 and 2011. 

The study also included a comparison sample of 75,184 children and adolescents aged 5–18 with no child welfare services contact during 2009–2011. 

The interventions delivered by child welfare services in Norway are largely divided into two primary categories: supportive intervention and out-of-home placement. 

Supportive interventions include improving parenting skills, promoting child development, providing supervision and control, facilitating cooperation with other services, assessments and treatments by other institutions, and offering housing support. 

Norway uses foster homes or child welfare institutions as a last resort. When supportive interventions fail to meet the child’s needs, the child welfare services can temporarily place the child in these facilities. If parents disagree, the county social welfare board decides based on a municipal request. 

The team adjusted for potential confounders: sex, age, parental socioeconomic status (father’s and mother’s education and income level), and marital status. 

Results:

With these adjustments, children and adolescents diagnosed with ADHD were over six times more likely to have any contact with child welfare services than their general population peers. This was equally true for males and females.  

Children and adolescents diagnosed with ADHD were also over six times more likely to receive supportive interventions from child welfare services. Again, there were no differences between males and females. 

Finally, children and adolescents diagnosed with ADHD were roughly seven times more likely to have an out-of-home placement than their general population peers. For males this rose to eight times more likely. 

Conclusion:

The team concluded, “This population-based study provides robust evidence of a higher rate and strong association between ADHD and contact with CWS [Child Welfare Service] compared to the general population in Norway.” 

July 8, 2025